Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Thierry André, Kimmie Ng et al.|The Lancet Oncology|2023Cited by 244
Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter StudyMiguel García-Pardo, A. Julian Muñoz, Laura Ortega et al.|Journal of Gastrointestinal Cancer|2021Cited by 4